Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a “peakless” profile (according to the insulin glargine package insert).
Scope of the Report:
This report focuses on the Insulin Glargine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Insulin glargine is a long-acting, man-made version of human insulin. Insulin glargine works by replacing the insulin that is normally produced by the body and by helping move sugar from the blood into other body tissues where it is Used for energy. It also stops the liver from producing more sugar.
There are two type of Insulin glargine, which are Single Dose Vial and Pre-filled Syringe in the market. Considering its function, Insulin glargine is Used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also Used to treat people with type 2 diabetes (condition in which the body does not Used insulin normally and, therefore, cannot control the amount of sugar in the blood) who need insulin to control their diabetes.
We can see that there are just a few companies produce Insulin glargine, the production of them almost approach to 70% of whole market. They have seted plant in Japan, China, German, India, North Americato produce Insulin glargine, and China is the largest plant for Insulin glargine in the world and also the largest consumption country. As the amount of diabetes of increasing of China, the Chinese market will be bigger than North America.
The Industry is affected by the economic development level and policy, so its important to put an eye to economic indexes and leaders prefer. With the global economic recovery, more and more people pay attention to care about personal health, especially in underdevelopment regions that have a large population and fast economic growth, the need of Insulin glargine will increase.
The worldwide market for Insulin Glargine is expected to grow at a CAGR of roughly 4.1% over the next five years, will reach 7240 million US$ in 2023, from 5690 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Single Dose Vial
Market Segment by Applications, can be divided into
Treat type2 diabetes
Treat type1 diabetes
There are 15 Chapters to deeply display the global Insulin Glargine market.
Chapter 1, to describe Insulin Glargine Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Insulin Glargine, with sales, revenue, and price of Insulin Glargine, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Insulin Glargine, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Insulin Glargine market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Insulin Glargine sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source